COSCIENS Biopharma Inc. Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset
COSCIENS Biopharma Inc. (CSCIF) reported Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset of $1.80 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset · last filed 2026-03-25
- COSCIENS Biopharma Inc. increase decrease through changes in foreign exchange rates net defined benefit liability asset for the quarter ending 2025-03-31 was $780.00K.
- COSCIENS Biopharma Inc. increase decrease through changes in foreign exchange rates net defined benefit liability asset for the quarter ending 2024-03-31 was -$527.00K, a 257.31% decline year-over-year.
- COSCIENS Biopharma Inc. increase decrease through changes in foreign exchange rates net defined benefit liability asset for the quarter ending 2023-03-31 was $335.00K.
- COSCIENS Biopharma Inc. increase decrease through changes in foreign exchange rates net defined benefit liability asset for the quarter ending 2022-03-31 was -$553.00K.
| Period end | Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset 3 month | Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset 6 month | Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset 9 month | Increase Decrease Through Changes In Foreign Exchange Rates Net Defined Benefit Liability Asset 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.80M 20-F · filed 2026-03-25 | |||
| 2025-09-30 | $2.33M 6-K · filed 2025-11-12 | |||
| 2025-06-30 | $2.26M 6-K · filed 2025-08-14 | |||
| 2025-03-31 | $780.00K 6-K · filed 2025-05-13 | |||
| 2024-12-31 | -$953.00K 20-F · filed 2026-03-25 | |||
| 2024-09-30 | $697.00K 6-K · filed 2024-11-12 | |||
| 2024-06-30 | -$273.00K 6-K · filed 2024-08-13 | |||
| 2024-03-31 | -$527.00K 6-K · filed 2024-05-16 | |||
| 2023-12-31 | $645.00K 20-F/A · filed 2024-07-17 | |||
| 2023-09-30 | -$297.00K 6-K · filed 2023-11-09 | |||
| 2023-06-30 | $262.00K 6-K · filed 2023-08-09 | |||
| 2023-03-31 | $335.00K 6-K · filed 2023-05-09 | |||
| 2022-12-31 | -$1.43M 20-F/A · filed 2024-07-17 | |||
| 2022-09-30 | -$3.05M 6-K · filed 2022-11-03 | |||
| 2022-06-30 | -$2.11M 6-K/A · filed 2022-08-04 | |||
| 2022-03-31 | -$553.00K 6-K · filed 2022-05-11 | |||
| 2021-12-31 | -$1.23M 20-F/A · filed 2024-02-15 | |||
| 2019-09-30 | -$638.00K 6-K · filed 2019-11-07 | |||
| 2019-06-30 | -$54.00K 6-K · filed 2019-08-13 | |||
| 2018-12-31 | -$653.00K 6-K · filed 2019-11-07 |